Gene therapy of type 2 diabetes mellitus: state of art
- Authors: Stafeev Y.S1,2, Menshikov MY.1, Parfyonova Y.V1,2
-
Affiliations:
- National Medical Research Centre for Cardiology of the Ministry of Health of the Russian Federation
- M.V. Lomonosov Moscow State University
- Issue: Vol 91, No 2 (2019)
- Pages: 149-152
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/32975
- DOI: https://doi.org/10.26442/00403660.2019.02.000042
- ID: 32975
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
Yu S Stafeev
National Medical Research Centre for Cardiology of the Ministry of Health of the Russian Federation; M.V. Lomonosov Moscow State University
Email: yuristafeev@gmail.com
м.н.с. лаб. ангиогенеза НИИЭК ФГБУ НМИЦ кардиологии, аспирант кафедры биохимии и молекулярной медицины факультета фундаментальной медицины ФГБОУ ВО «МГУ им. М.В. Ломоносова» Moscow, Russia
M Yu Menshikov
National Medical Research Centre for Cardiology of the Ministry of Health of the Russian Federationд.б.н., в.н.с. лаб. ангиогенеза НИИЭК ФГБУ «НМИЦ кардиологии» Moscow, Russia
Ye V Parfyonova
National Medical Research Centre for Cardiology of the Ministry of Health of the Russian Federation; M.V. Lomonosov Moscow State Universityд.м.н., зав. лаб. ангиогенеза и директор НИИЭК «ФГБУ НМИЦ кардиологии», зав. лаб. постгеномных технологий в медицине факультета фундаментальной медицины ФГБОУ ВО «МГУ им. М.В. Ломоносова» Moscow, Russia
References
- Naldini L. Medicine. A comeback for gene therapy. Science. 2009;326:805-6. doi: 10.1126/science.1181937
- Herzog R.W, Cao O, Srivastava A. Two decades of clinical gene therapy - success is finally mounting. Discov Med. 2010;9:105-11.
- Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science. 2013;342:1432-3. doi: 10.1126/science.342.6165.1432
- Williams P.D, Kingston P.A. Plasmid - mediated gene therapy for cardiovascular disease. Cardiovasc Res. 2011;91:565-76. doi: 10.1093/cvr/cvr197
- Laitinen M, Pakkanen T, Donetti E, Baetta R, Luoma J, Lehtolainen P, Viita H, Agrawal R, Miyanohara A, Friedmann T, Risau W, Martin J.F, Soma M, Ylä-Herttuala S. Gene transfer into the carotid artery using an adventitial collar: comparison of the effectiveness of the plasmid - liposome complexes, retroviruses, pseudotyped retroviruses, and adenoviruses. Hum Gene Ther. 1997;8:1645-50. doi: 10.1089/hum.1997.8.14-1645
- Edwards C.M. GLP-1: target for a new class of antidiabetic agents? J R Soc Med. 2004;97:270-4.
- Herzberg-Schäfer S, Heni M, Stefan N, Häring H.U, Fritsche A. Impairment of GLP1-induced insulin secretion: role of genetic background, insulin resistance and hyperglycaemia. Diabetes Obes Metab. 2012;14:85-90. doi: 10.1111/j.1463-1326.2012.01648.x
- Domínguez Avila J.A, Rodrigo García J, González Aguilar G.A, de la Rosa L.A. The antidiabetic mechanisms of polyphenols related to increased glucagon - like peptide-1 (GLP1) and insulin signaling. Molecules. 2017;22:E933. doi: 10.3390/molecules22060903
- Iwaki M, Matsuda M, Maeda N, Funahashi T, Matsuzawa Y, Makishima M, Shimomura I. Induction of adiponectin, a fat - derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes. 2003;52:1655-63. doi: 10.2337/diabetes.52.7.1655
- Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. 2006;116:1784-92. doi: 10.1172/JCI29126
- Fisman E.Z, Tenenbaum A. Adiponectin: a manifold therapeutic target for metabolic syndrome, diabetes, and coronary disease? Cardiovasc Diabetol. 2014;13:103. doi: 10.1186/1475-2840-13-103
- Choi S, Oh S, Lee M, Kim S.W. Glucagon - like peptide-1 plasmid construction and delivery for the treatment of type 2 diabetes. Mol Ther. 2005;12:885-91. doi: 10.1016/j.ymthe.2005.03.039
- Parsons G.B, Souza D.W, Wu H, Yu D, Wadsworth S.G, Gregory R.J, Armentano D. Ectopic expression of glucagon - like peptide 1 for gene therapy of type II diabetes. Gene Ther. 2007;14:38-48. doi: 10.1038/sj.gt.3302842
- Jean M, Alameh M, Buschmann M.D, Merzouki A. Effective and safe gene - based delivery of GLP-1 using chitosan/plasmid-DNA therapeutic nanocomplexes in an animal model of type 2 diabetes. Gene Ther. 2011;18:807-16. doi: 10.1038/gt.2011.25
- Vilsboll T. Liraglutide: a new treatment for type 2 diabetes. Drugs Today (Barc.). 2009;45:101-13. doi: 10.1358/dot.2009.45.2.1336104
- Verges B, Bonnard C, Renard E. Beyond glucose lowering: glucagon - like peptide-1 receptor agonists, body weight and the cardiovascular system. Diabetes Metab. 2011;37:477-88. doi: 10.1016/j.diabet.2011.07.001
- Garber A.J. Liraglutide in oral antidiabetic drug combination therapy. Diabetes Obes Metab. 2012;14:13-9. doi: 10.1111/j.1463-1326.2012.01574.x
- Kim P.H, Lee V, Nam K, Kim S.W. Enhanced incretin effects of exendin-4 expressing chimeric plasmid based on two - step transcription amplification system with dendritic bioreducible polymer for the treatment of type 2 diabetes. J Gene Ther. 2013;1:7-15. doi: 10.13188/2381-3326.1000002
- Park J.H, Lee M, Kim S.W. Non - viral adiponectin gene therapy into obese type 2 diabetic mice ameliorates insulin resistance. J Control Release. 2006;114:118-25. doi: 10.1016/j.jconrel.2006.05.008
- Nan M.H, Park J.S, Myung C.S. Construction of adiponectin - encoding plasmid DNA and gene therapy of non - obese type 2 diabetes mellitus. J Drug Target. 2010;18:67-77. doi: 10.3109/10611860903225719
- Kandasamy A.D, Sung M.M, Boisvenue J.J, Barr A.J, Dyck J.R. Adiponectin gene therapy ameliorates high - fat, high - sucrose diet - induced metabolic perturbations in mice. Nutr Diabetes. 2012;2:e45. doi: 10.1038/nutd.2012.18
- Halenova T, Savchuk O, Ostapchenko L, Chursov A, Fridlyand N, Komissarov A, Venanzi F, Kolesnikov I, Sufianov A, Sherman M, Gabai L, Shneider A. P62 plasmid can alleviate diet - induced obesity and metabolic dysfunctions. Oncotarget. 2017;8:56030-40. doi: 10.18632/oncotarget.19840
- Jimenez V, Muñoz S, Casana E, Mallol C, Elias I, Jambrina C, Ribera A, Ferre T, Franckhauser S, Bosch F. In vivo adeno - associated viral vector - mediated genetic engineering of white and brown adipose tissue in adult mice. Diabetes. 2013;62:4012-22. doi: 10.2337/db13-0311
- O'Neill S.M, Hinkle C, Chen S.J, Sandhu A, Hovhannisyan R, Stephan S, Lagor W.R, Ahima R.S, Johnston J.C, Reilly M.P. Targeting adipose tissue via systemic gene therapy. Gene Ther. 2014;21:653-61. doi: 10.1038/gt.2014.38
- Gomez-Banoy N, Lo J.C. Genetic manipulation with viral vectors to assess metabolism and adipose tissue function. Meth Mol Biol. 2017;1566:109-24. doi: 10.1007/978-1-4939-6820-6_11
- Riedel M.J, Gaddy D.F, Asadi A, Robbins P.D, Kieffer T.J. DsAAV8-mediated expression of glucagon - like peptide-1 in pancreatic beta - cells ameliorates streptozotocin - induced diabetes. Gene Ther. 2010;17:171-80. doi: 10.1038/gt.2009.143
- Lee Y, Kwon M.K, Kang E.S, Park Y.M, Choi S.H, Ahn C.W, Kim K.S, Park C.W, Cha B.S, Kim S.W, Sung J.K, Lee E.J, Lee H.C. Adenoviral vector - mediated glucagon - like peptide 1 gene therapy improves glucose homeostasis in Zucker diabetic fatty rats. J Gene Med. 2008;10:260-8. doi: 10.1002/jgm.1153
- Tasyurek H.M, Altunbas H.A, Balci M.K, Griffith T.S, Sanlioglu S. Therapeutic potential of lentivirus - mediated glucagon - like peptide-1 gene therapy for diabetes. Hum Gene Ther. 2018;29:802-15. doi: 10.1089/hum.2017.180
- Kojima S, Asakawa A, Amitani H, Sakoguchi T, Ueno N, Inui A, Kalra S.P. Central leptin gene therapy, a substitute for insulin therapy to ameliorate hyperglycemia and hyperphagia, and promote survival in insulin - deficient diabetic mice. Peptides. 2009;30:962-6. doi: 10.1016/j.peptides.2009.01.007
- Wang Y, Asakawa A, Inui A, Kosai K. Leptin gene therapy in the fight against diabetes. Expert Opin Biol Ther. 2010;10:1405-14. doi: 10.1517/14712598.2010.512286
- Lee M.W, Odegaard J.I, Mukundan L, Qiu Y, Molofsky A.B, Nussbaum J.C, Yun K, Locksley R.M, Chawla A. Activated type 2 innate lymphoid cells regulate beige fat biogenesis. Cell. 2015;160:74-87. doi: 10.1016/j.cell.2014.12.011
- Stafeev I.S, Michurina S.S, Podkuychenko N.V, Vorotnikov A.V, Menshikov M.Y, Parfyonova Ye.V. Interleukin-4 restores insulin sensitivity in lipid - induced insulin resistant adipocytes. Biochemistry (Mosc). 2018;83:498-506. doi: 10.1134/S0006297918050036
- Michurina S, Stafeev I, Beloglazova I, Molokotina Y, Shevchenko E, Vorotnikov A, Menshikov M, Parfyonova Ye. Lentiviral transfer of interleukin 4 gene to 3T3-L1 adipocytes prevents development of lipid - induced insulin resistance. Eur Heart J. 2018;39:492. doi: 10.1093/eurheartj/ehy565.P2524